US OptionsDetailed Quotes
XBIT250117C5000
- 0.01
- -0.24-96.00%
15min DelayClose Dec 27 16:00 ET
0.05High0.01Low
0.05Open0.25Pre Close4 Volume1 Open Interest5.00Strike Price12.00Turnover63.78%IV31.84%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.0444Delta0.1613Gamma380.00Leverage Ratio-0.0013Theta0.0001Rho16.86Eff Leverage0.0009Vega
XBiotech Stock Discussion
XBiotech (NASDAQ: XBIT) recently announced promising data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Named 1-BETTER, this study focused on evaluating Natrunix, an anti-interleukin-1alpha antibody, in combination with a well-established chemotherapy regimen comp...
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
XBiotech (NASDAQ: XBIT) announced promising results from its Phase 1/2 trial for advanced pancreatic cancer treatment using Natrunix in combination with a standard chemotherapy regimen. The study, titled 1-BETTER, enrolled 65 subjects who received either the Natrunix combination or a placebo. Key findings include a 28% reduction in signif...
Where can check this information?
If I have 10 share....
Where is the money? 🧐
No comment yet